Ongoing trials aim to evaluate PD-1-, PD-L1- or CTLA4-targeting ICIs in combination with standard anti-Her-2/neu therapy for Her-2/neu-positive breast cancer (Table 1). This evidence concerns the gene PDCD1 and breast carcinoma.